Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab

• Glavni autori: Erminia Ridolo (Autor), Francesco Pucciarini (Autor), Maria Cristina Nizi (Autor), Eleni Makri (Autor), Paola Kihlgren (Autor), Lorenzo Panella (Autor), Cristoforo Incorvaia (Autor)
• Format: Knjiga
• Izdano: Taylor & Francis Group, 2020-10-01T00:00:00Z.
• Teme: article
• Online pristup: Connect to this object online.

The introduction of biologics for the treatment of patients with refractory asthma represented a marked therapeutic advance. For more than 10 y, the only biologic available has been the monoclonal anti-IgE antibody omalizumab, reserved for patients with asthma caused by perennial allergen. In recent...